Latest Exelixis Inc. Stories
NEW YORK, Jan. 5, 2015 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer.
NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company.
LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Editor Note: For more information about this release, please scroll to bottom. LONDON, March 24, 2014 /PRNewswire/ -- On Friday, March 20, 2014, the NASDAQ Composite
NEW YORK, Sept.
Exelixis, Inc. (Nasdaq:EXEL) today reported preliminary phase 1 data from a dose-escalation trial of XL228 in patients with advanced malignancies (solid tumors, lymphoma, or multiple myeloma) for which standard therapies are no longer effective.
- A bereavement by loss of parents or children; the state of being orbate; orbation.